Short answer
Stoke Therapeutics, Inc. (STOK) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Three Class I directors re-elected for terms ending at the 2029 annual meeting.
Stoke Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Three Class I directors re-elected for terms ending at the 2029 annual meeting
- Ernst & Young LLP appointment ratified for fiscal year ending December 31, 2026
- Executive compensation approved on an advisory basis, with 36,436,275 votes for and 13,565,293 against
- Compensation vote’s substantial opposition signals shareholder scrutiny of named executive officer pay
- Director support varied materially, with Adrian Krainer receiving 36,531,612 votes for and 13,499,371 withheld
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stoke Therapeutics, Inc. 8-K filings
Get the next STOK 8-K as it lands
Follow STOK for push alerts, or ask the research agent what this filing means.